Skip to content

Contact +44 (0) 20 7060 7474 email us

Clinical Trials

Coronary Stent Clinical Trial Analysis

 

Publication Date July 2009
Publisher Global Markets Direct
Product Type
Pages 73
ISBN Number not applicable
Product Code GMD02879

Price

£655.00
approximately: $1,003 | €730

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

Global Markets Direct's "Coronary Stent Clinical Trials Analysis" is an essential source of data and information pertaining to product clinical trials being carried out by Coronary Stent manufacturers, globally. The report provides exhaustive information on each clinical investigation study with coverage detailed coverage on the pipeline products these trials are being carried out for.

Scope

  • The report provides analysis and review of the key clinical trials being carried out globally and across key Coronary Stent market categories - Drug Eluting Stent (DES),Bare Metal Stent
  • The report covers information on each product being clinically tested with detailed coverage on the pipeline product profile, the indication it's being investigated for etc.
  • The report provides an in-depth analysis of the clinical trials with information on trial phase, trial 0status, trial acronym, purpose, inclusion and exclusion criteria, description, design, intervention, investigator information, primary and secondary end-points and trial results
  • The report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by Global Markets Direct's team of industry experts.

Reasons to Buy

  • Effectively plan your Mergers and Acquisitions and partnership strategies by identifying companies with the most promising pipeline.
  • Stay ahead of the information curve in the fast changing Coronary Stent market.
  • Plan in-licensing and out-licensing opportunities through review of pipeline products and technologies.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Proactively plan and execute your competitive strategies by identifying clinical trials status of the leading competitive products in pipeline.
  • Stay ahead of competition by understanding the changing competitive landscape in specific geographies.

Contents

  • 1 List of Tables
  • 1.2 List of Figures
  • 2 Coronary Stent Clinical Trials
    • 2.1 Coronary Stent Clinical Trial By Equipment Type
    • 2.2 Coronary Stent Clinical Trials By Trial Phase and Trial Status
    • 2.3 Coronary Stent Pipeline Products By Development Stage
    • 2.4 Coronary Stent Pipeline Products By Therapy Area
    • 2.5 Coronary Stent Pipeline Products By News Summary
    • 2.6 Coronary Stent TAXUS Element Paclitaxel-Eluting Coronary Stent System
      • 2.6.1 A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions
      • 2.6.2 A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions
      • 2.6.3 A Prospective Evaluation in a Non-Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions in Small Vessels
  • 3 Recent Developments
    • 3.1 Product News
      • 3.1.1 Jun 16, 2009: Abbott Announces Enrollment Of First Patient In SPIRIT PRIME Trial Evaluating XIENCE PRIME Everolimus Eluting Coronary Stent System
      • 3.1.2 Jun 04, 2009: XTENT's Custom NX Drug Eluting Stent System Receives Conditional IDE Approval To Begin Two Pivotal Trials
      • 3.1.3 May 29, 2009: Devax Announces Conditional IDE Approval To Commence DIVERGE II Trial Of AXXESS System
      • 3.1.4 May 27, 2009: Boston Scientific Receives FDA Approval For Next-Generation TAXUS Liberte Atom Stent System
      • 3.1.5 May 20, 2009: Treatment Of Complex Coronary Artery Disease With TAXUS Express2 Stent System Found To Be More Cost Effective Than Bypass Surgery In SYNTAX Analysis
      • 3.1.6 May 19, 2009: Boston Scientific Announces Launch Of Third-Generation Platinum Chromium Drug-Eluting Stent In Select Markets
      • 3.1.7 May 19, 2009: Cordis Presents Results Of Cypher Sirolimus-Eluting Coronary Stent During Late Breaking Clinical Trials At EuroPCR
      • 3.1.8 May 19, 2009: Cordis' Nevo Sirolimus-Eluting Coronary Stent Shows Superior Results In Comparison To Taxus Liberte Stent
      • 3.1.9 May 15, 2009: Medtronic Presents New data Of Endeavor Stent's Long-Term Safety And Efficacy At Interventional Cardiology Congress
      • 3.1.10 May 14, 2009: Medtronic Announces The Completion Of Enrollment In RESOLUTE International Trial
      • 3.1.11 May 12, 2009: Johnson & Johnson (JNJ) To Host A Conference Call For Financial Analysts To Review Trial Results From NEVO RES I
      • 3.1.12 May 11, 2009: Boston Scientific Welcomes Publication Of Data From The Swedish National Registry
      • 3.1.13 Apr 28, 2009: ITGI Medical, Ltd Receives HUD (Humanitarian Use Device) Designation To Over And Under And Aneugraft Pericardium Covered Stents From FDA
      • 3.1.14 Apr 22, 2009: OrbusNeich Presents Results Of Genous Bio-Engineered R Stent In Higher Risk Patients
      • 3.1.15 Apr 09, 2009: ZEST Clinical Data Shows Better Clinical Outcomes Compare To TAXUS LIBERTE And ENDEAVOR Stents
      • 3.1.16 Mar 31, 2009: Medtronic Announces International Market Release Of Driver Sprint RX Coronary Stent System
      • 3.1.17 Mar 30, 2009: Medtronic Receives Regulatory Approval For Endeavor Drug-Eluting Coronary Stent In Japan
      • 3.1.18 Mar 29, 2009: Abbott's XIENCE V Shows Increasing Clinical Advantages Over TAXUS Express2/TAXUS Liberte Between Two And Three Years
      • 3.1.19 Mar 28, 2009: Medtronic's Endeavor Stent Shows Consistent And Sustained Safety And Effectiveness Benefits At Two Years
      • 3.1.20 Mar 24, 2009: Abbott Commences The Next Phase Of Clinical Trial Of Its Fully Bioabsorbable Drug Eluting Coronary Stent System
      • 3.1.21 Mar 16, 2009: Cordis Announces NEVO II Clinical Trial Comparing The Nevo Sirolimus-Eluting Coronary Stent To The Xience Stent
      • 3.1.22 Mar 16, 2009: Cordis Announces NEVO II Clinical Trial Comparing The Nevo Sirolimus-Eluting Coronary Stent To The Xience Stent
      • 3.1.23 Mar 12, 2009: Abbott Announces Publication Of Two-Year Results Of Fully Bioabsorbable Drug Eluting Stent
      • 3.1.24 Mar 04, 2009: Micell Technologies To Showcase Its Rapid Absorption Polymer DES System At CRT 2009
      • 3.1.25 Feb 16, 2009: BIOTRONIK Launches A New Generation Cobalt Chromium Stent System With PROBIO Coating
      • 3.1.26 Feb 05, 2009: Final Modules Of Boston Scientific's Second-Generation Small Vessel And Long Lesion Stents Submitted To FDA
      • 3.1.27 Feb 02, 2009: Medtronic Announces The Completion Of Patient Enrollment In Global Head-To-Head Stent-Safety Study
      • 3.1.28 Jan 28, 2009: TAXUS Liberte Drug-Eluting Stent System Of Boston Scientific Gains Japanese Approval
      • 3.1.29 Jan 26, 2009: Pivotal Two Year Results On XIENCE V Drug Eluting Stent Data Published
      • 3.1.30 Jan 22, 2009: Isotechnika Announces Enrollment Completion Of Its Partner Atrium's CONFIRM 1 Trial For Voclosporin Coated Coronary Stent System
    • 3.2 Product Approvals
      • 3.2.1 May 27, 2009: Boston Scientific Receives FDA Approval For Next-Generation TAXUS Liberte Atom Stent System
      • 3.2.2 Apr 28, 2009: ITGI Medical, Ltd Receives HUD (Humanitarian Use Device) Designation To Over And Under And Aneugraft Pericardium Covered Stents From FDA
      • 3.2.3 Mar 30, 2009: Medtronic Receives Regulatory Approval For Endeavor Drug-Eluting Coronary Stent In Japan
      • 3.2.4 Jan 28, 2009: TAXUS Liberte Drug-Eluting Stent System Of Boston Scientific Gains Japanese Approval
      • 3.2.5 Dec 08, 2008: InspireMD's MGuard Coronary Stent System Approved In Israel
      • 3.2.6 Oct 23, 2008: FDA Approves Boston Scientific's Carotid Artery Stent
      • 3.2.7 Oct 10, 2008: Boston Scientific Announces FDA Approval of Second-Generation TAXUS Liberte Drug-Eluting Stent
      • 3.2.8 Sep 25, 2008: Boston Scientific Corporation Announces FDA Approval Of TAXUS Express2 Atom Stent System
      • 3.2.9 Sep 25, 2008: Boston Scientific Corporation Announces FDA Approval Of TAXUS Express2 Paclitaxel-Eluting Coronary Stent System For The Treatment Of In-Stent Restenosis
    • 3.3 Clinical Trials
      • 3.3.1 Jun 16, 2009: Abbott Announces Enrollment Of First Patient In SPIRIT PRIME Trial Evaluating XIENCE PRIME Everolimus Eluting Coronary Stent System
      • 3.3.2 Jun 04, 2009: XTENT's Custom NX Drug Eluting Stent System Receives Conditional IDE Approval To Begin Two Pivotal Trials
      • 3.3.3 May 29, 2009: Devax Announces Conditional IDE Approval To Commence DIVERGE II Trial Of AXXESS System
      • 3.3.4 May 20, 2009: Treatment Of Complex Coronary Artery Disease With TAXUS Express2 Stent System Found To Be More Cost Effective Than Bypass Surgery In SYNTAX Analysis
      • 3.3.5 May 19, 2009: Cordis' Nevo Sirolimus-Eluting Coronary Stent Shows Superior Results In Comparison To Taxus Liberte Stent
      • 3.3.6 May 19, 2009: Cordis Presents Results Of Cypher Sirolimus-Eluting Coronary Stent During Late Breaking Clinical Trials At EuroPCR
      • 3.3.7 May 15, 2009: Medtronic Presents New data Of Endeavor Stent's Long-Term Safety And Efficacy At Interventional Cardiology Congress
      • 3.3.8 May 12, 2009: Johnson & Johnson (JNJ) To Host A Conference Call For Financial Analysts To Review Trial Results From NEVO RES I
      • 3.3.9 May 11, 2009: Boston Scientific Welcomes Publication Of Data From The Swedish National Registry
      • 3.3.10 Apr 22, 2009: OrbusNeich Presents Results Of Genous Bio-Engineered R Stent In Higher Risk Patients
      • 3.3.11 Apr 09, 2009: ZEST Clinical Data Shows Better Clinical Outcomes Compare To TAXUS LIBERTE And ENDEAVOR Stents
      • 3.3.12 Mar 29, 2009: Abbott's XIENCE V Shows Increasing Clinical Advantages Over TAXUS Express2/TAXUS Liberte Between Two And Three Years
      • 3.3.13 Mar 28, 2009: Medtronic's Endeavor Stent Shows Consistent And Sustained Safety And Effectiveness Benefits At Two Years
      • 3.3.14 Mar 24, 2009: Abbott Commences The Next Phase Of Clinical Trial Of Its Fully Bioabsorbable Drug Eluting Coronary Stent System
      • 3.3.15 Mar 16, 2009: Cordis Announces NEVO II Clinical Trial Comparing The Nevo Sirolimus-Eluting Coronary Stent To The Xience Stent
      • 3.3.16 Mar 16, 2009: Cordis Announces NEVO II Clinical Trial Comparing The Nevo Sirolimus-Eluting Coronary Stent To The Xience Stent
      • 3.3.17 Mar 12, 2009: Abbott Announces Publication Of Two-Year Results Of Fully Bioabsorbable Drug Eluting Stent
      • 3.3.18 Feb 02, 2009: Medtronic Announces The Completion Of Patient Enrollment In Global Head-To-Head Stent-Safety Study
      • 3.3.19 Jan 26, 2009: Pivotal Two Year Results On XIENCE V Drug Eluting Stent Data Published
      • 3.3.20 Jan 22, 2009: Isotechnika Announces Enrollment Completion Of Its Partner Atrium's CONFIRM 1 Trial For Voclosporin Coated Coronary Stent System
  • 4 Appendix
    • 4.1 Methodology
      • 4.1.1 Coverage
      • 4.1.2 Secondary Research
      • 4.1.3 Primary Research
      • 4.1.4 Expert Panel Validation
    • 4.2 Contact Us
    • 4.3 About Global Markets Direct
    • 4.4 Disclaimer
  • 1 List of Tables
    • Table 1: Coronary Stent Clinical Trial By Equipment Type
    • Table 2: Coronary Stent Clinical Trials By Trial Phase and Trial Status
    • Table 3: Coronary Stent Pipeline Products By Development Stage
    • Table 4: Coronary Stent Pipeline Products By Therapy Area
    • Table 5: Coronary Stent Pipeline Products By News Summary
    • Table 6: TAXUS Element Paclitaxel-Eluting Coronary Stent System - A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions
    • Table 7: TAXUS Element Paclitaxel-Eluting Coronary Stent System - A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions
    • Table 8: TAXUS Element Paclitaxel-Eluting Coronary Stent System - A Prospective Evaluation in a Non-Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions in Small Vessels
  • 1.2 List of Figures
    • Figure 1: Global Markets Direct Methodology